Completed PHASE2 NCT00010413

Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus

Sponsor: Johns Hopkins University

Conditions Pemphigus

Interventions cyclophosphamide filgrastim

Updated 5 times since 2017 Last updated: Oct 1, 2008 Started: Apr 30, 1999 Primary completion: Aug 31, 2007

This PHASE2 trial investigates Pemphigus and is currently completed. Johns Hopkins University leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johns Hopkins University

Data source: Office of Rare Diseases (ORD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States